GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jazz Pharmaceuticals PLC (NAS:JAZZ) » Definitions » Price-to-Free-Cash-Flow

Jazz Pharmaceuticals (Jazz Pharmaceuticals) Price-to-Free-Cash-Flow

: 7.54 (As of Today)
View and export this data going back to 2007. Start your Free Trial

As of today (2024-04-18), Jazz Pharmaceuticals's share price is $109.27. Jazz Pharmaceuticals's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $14.49. Hence, Jazz Pharmaceuticals's Price-to-Free-Cash-Flow Ratio for today is 7.54.

The historical rank and industry rank for Jazz Pharmaceuticals's Price-to-Free-Cash-Flow or its related term are showing as below:

JAZZ' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.39   Med: 15.6   Max: 91.8
Current: 7.48

During the past 13 years, Jazz Pharmaceuticals's highest Price-to-Free-Cash-Flow Ratio was 91.80. The lowest was 7.39. And the median was 15.60.

JAZZ's Price-to-Free-Cash-Flow is ranked better than
87.14% of 210 companies
in the Biotechnology industry
Industry Median: 30.53 vs JAZZ: 7.48

Jazz Pharmaceuticals's Free Cash Flow per Share for the three months ended in Dec. 2023 was $2.00. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $14.49.

During the past 12 months, the average Free Cash Flow per Share Growth Rate of Jazz Pharmaceuticals was 17.70% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was 16.50% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 6.70% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 13.70% per year.

During the past 13 years, Jazz Pharmaceuticals's highest 3-Year average Free Cash Flow per Share Growth Rate was 51.90% per year. The lowest was -15.90% per year. And the median was 14.30% per year.


Jazz Pharmaceuticals Price-to-Free-Cash-Flow Historical Data

The historical data trend for Jazz Pharmaceuticals's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jazz Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.46 17.92 10.38 12.88 8.45

Jazz Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Free-Cash-Flow Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.88 10.57 8.67 10.95 8.45

Competitive Comparison

For the Biotechnology subindustry, Jazz Pharmaceuticals's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jazz Pharmaceuticals Price-to-Free-Cash-Flow Distribution

For the Biotechnology industry and Healthcare sector, Jazz Pharmaceuticals's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Jazz Pharmaceuticals's Price-to-Free-Cash-Flow falls into.



Jazz Pharmaceuticals Price-to-Free-Cash-Flow Calculation

Jazz Pharmaceuticals's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=109.27/14.487
=7.54

Jazz Pharmaceuticals's Share Price of today is $109.27.
Jazz Pharmaceuticals's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $14.49.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Jazz Pharmaceuticals  (NAS:JAZZ) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Jazz Pharmaceuticals Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Jazz Pharmaceuticals's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Jazz Pharmaceuticals (Jazz Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
Waterloo Road, Fifth Floor, Waterloo Exchange, Dublin, IRL, D04 E5W7
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Executives
Jennifer E. Cook director C/O DENALI THERAPEUTICS INC., 151 OYSTER POINT BLVD., 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
Mark Douglas Smith director C/O TELADOC HEALTH, INC., 2 MANHATTANVILLE ROAD, SUITE 203, PURCHASE NY 10577
Neena M Patil officer: SVP, General Counsel JAZZ PHARMACEUTICALS, 3170 PORTER DRIVE, PALO ALTO CA 94304
Patricia Carr officer: VP, Finance& PAO JAZZ PHARMACEUTICALS, 3170 PORTER DRIVE, PALO ALTO CA 94304
Heather Ann Mcsharry director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Patrick G Enright director, 10 percent owner CO LONGITUDE CAPITAL PARTNERS LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
Norbert G Riedel director BAXTER INTERNATIONAL INC, ONE BAXTER PKWY DF2-1W, DEERFIELD IL 60015
Catherine A. Sohn director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Rick E Winningham director 901 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Peter Gray director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Anne Oriordan director HOUSE 120, TAI HANG HAU VILLAGE, LOBSTER BAY, CLEARWATER BAY K3 HK
Kenneth W O'keefe director C/O BEECKEN PETTY O'KEEFE & COMPANY, 131 S. DEARBORN STREET, SUITE 2800, CHICAGO IL 60603
Mary Elizabeth Henderson officer: SVP, Technical Operations 3170 PORTER DRIVE, PALO ALTO CA 94304
Renee D Gala officer: EVP & CFO 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Kim Sablich officer: EVP & GM, North America C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, BRISBANE CA 94005

Jazz Pharmaceuticals (Jazz Pharmaceuticals) Headlines

From GuruFocus